RORA and diabetes mellitus: Our result showed that offspring from the maternal diabetes (STZ/VEH) treatment group displayed significantly decreased ultrasonic vocalizations (P < 0.0001) compared to CTL/VEH treatment; both SOD mimetic (STZ/MnTBAP) or RORA agonist (STZ/SR1078) partly reversed this effect (P < 0.01, see Fig. 2a).